Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer With Liver Metastases at ASCO 2024
Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer With Liver Metastases at ASCO 2024
HOLON, Israel, April 25, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE:CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that it will present new clinical data on COM701 (anti-PVRIG) in triple combination with COM902 (anti-TIGIT) and pembrolizumab in microsatellite stable colorectal cancer at the American Society of Clinical Oncology (ASCO) annual meeting on May31-June 4 2023, in Chicago, Illinois.
以色列霍隆，2024年4月25日 /PRNewswire/ — Compugen Ltd.（納斯達克股票代碼：CGEN）（TASE: CGEN）是一家臨床階段的癌症免疫療法公司，也是計算靶標發現的先驅，今天宣佈將在美國發布有關 COM701（抗 PVRIG）與 COM902（抗蒂吉特）和pembrolizumab三聯用治療微衛星穩定結直腸癌的新臨床數據臨床腫瘤學會（ASCO）年會將於2023年5月31日至6月4日在伊利諾伊州芝加哥舉行。
Poster Presentation Details:
海報展示詳情：
Title: Preliminary antitumor activity of COM701 in combination with COM902 and pembrolizumab in patients with MSS-CRC and liver metastases
標題： COM701 與 COM902 和 pembrolizumab 聯合用對 MSS-CRC 和肝轉移患者的初步抗腫瘤活性
Abstract Number: 3597
摘要編號： 3597
Session Title: Gastrointestinal Cancer - Colorectal and Anal
會議標題： 胃腸道癌——結直腸癌和****癌
Lead Author: Dr. Manish Sharma
主要作者： 馬尼什·夏爾馬博士
Date: Saturday, June 1, 2024; 1:30PM-4:30PM CDT
日期： 2024 年 6 月 1 日，星期六；中部夏令時間下午 1:30 至下午 4:30
About Compugen
關於 Compuge
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has developed two proprietary product candidates: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Compugen also has a clinical stage partnered program, rilvegostomig (previously AZD2936), a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical stage anti-TIGIT antibody, COM902, in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, of which the most advanced program, COM503, is in IND enabling studies is licensed to Gilead. COM503 is a potential first-in-class, high affinity antibody which blocks the interaction between IL-18 binding protein and IL-18, thereby freeing natural IL-18 in the tumor microenvironment to inhibit cancer growth. Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.
Compugen是一家臨床階段的治療發現和開發公司，利用其廣泛適用的預測計算發現能力來確定開發癌症免疫療法的新藥物靶標和生物學路徑。Compugen開發了兩種專有候選產品：COM701，一種潛在的同類首創的抗PVRIG抗體，以及一種潛在的針對TIGIT治療實體瘤的同類最佳抗體 COM902。Compugen還有一個臨床階段的合作項目，即rilvegostomig（前身爲 AZD2936），這是一種PD-1/TIGIT雙特異性抗體，其TIGIT成分來自Compugen的臨床階段抗Tigit抗體 COM902，由阿斯利康通過許可協議開發雙特異性和多特異性抗體。此外，該公司的早期免疫腫瘤學項目的治療渠道包括旨在解決各種免疫耐藥機制的項目，其中最先進的項目，即 COM503，正在進行臨床研究，已獲吉利德的許可。COM503 是一種潛在的同類首創的高親和力抗體，它阻斷 IL-18 結合蛋白與 IL-18 之間的相互作用，從而釋放腫瘤微環境中的天然 IL-18 以抑制癌症的生長。Compugen總部位於以色列，在加利福尼亞州舊金山設有辦事處。Compugen的股票在納斯達克和特拉維夫證券交易所上市，股票代碼爲CGEN。
Company contact:
公司聯繫人：
Yvonne Naughton, Ph.D.
Head of Investor Relations and Corporate Communications
Email: [email protected]
Tel: +1 (628) 241-0071
伊馮娜·諾頓，博士
投資者關係和企業傳播主管
電子郵件：[電子郵件保護]
電話：+1 (628) 241-0071
SOURCE Compugen Ltd.
來源 Compugen Ltd.
譯文內容由第三人軟體翻譯。